Taken together, these data suggest that although the inhibition of the C3a/C3aR axis represents a promising immunotherapeutic option against pancreatic cancer, its combination with radiotherapy, delivered prior to the C3a/C3aR inhibition holds a greater therapeutic benefit. Here, C3 is linked to pancreatic neoplasm.